LivaNova/$LIVN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About LivaNova
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
Ticker
$LIVN
Sector
Primary listing
Industry
Health Care Equipment and Supplies
Headquarters
Employees
2,900
Website
LivaNova Metrics
BasicAdvanced
$2.4B
-
-$4.09
0.91
-
Price and volume
Market cap
$2.4B
Beta
0.91
52-week high
$54.47
52-week low
$32.48
Average daily volume
544K
Financial strength
Current ratio
1.579
Quick ratio
1.268
Long term debt to equity
57
Total debt to equity
65.537
Interest coverage (TTM)
2.93%
Profitability
EBITDA (TTM)
225.115
Gross margin (TTM)
69.45%
Net profit margin (TTM)
-17.42%
Operating margin (TTM)
14.33%
Effective tax rate (TTM)
-15.01%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
4.55%
Return on equity (TTM)
-19.70%
Valuation
Price to revenue (TTM)
1.861
Price to book
2.3
Price to tangible book (TTM)
66.51
Price to free cash flow (TTM)
16.308
Free cash flow yield (TTM)
6.13%
Free cash flow per share (TTM)
267.79%
Growth
Revenue change (TTM)
7.62%
Earnings per share change (TTM)
583.36%
3-year revenue growth (CAGR)
7.45%
3-year earnings per share growth (CAGR)
27.53%
What the Analysts think about LivaNova
Analyst ratings (Buy, Hold, Sell) for LivaNova stock.
Bulls say / Bears say
Wolfe Research upgraded LivaNova's stock rating to 'Outperform' with a price target of $60, citing attractive valuation and resolution of legal issues in Italy. (Investing.com)
LivaNova reported first-quarter 2025 earnings per share of $0.88, surpassing analyst expectations of $0.76, and raised its full-year revenue growth guidance to 6-7%. (Nasdaq)
The company plans to increase the capacity of its oxygenator products, which account for approximately 30% of total revenue, enhancing supply capabilities from 2026 onwards. (Investing.com)
LivaNova reported a net loss of $327.3 million in the first quarter of 2025, indicating ongoing profitability challenges. (Nasdaq)
The company's trailing twelve months EPS is -4.09, reflecting negative earnings and potential concerns about financial health. (StockAnalysis.com)
LivaNova's stock is trading below its 200-day moving average of $46.38, suggesting potential bearish sentiment among investors. (DirectorsTalkInterviews)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
LivaNova Financial Performance
Revenues and expenses
LivaNova Earnings Performance
Company profitability
LivaNova News
AllArticlesVideos
CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy
Business Wire·2 months ago
LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance
Business Wire·3 months ago
LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for LivaNova stock?
LivaNova (LIVN) has a market cap of $2.4B as of July 28, 2025.
What is the P/E ratio for LivaNova stock?
The price to earnings (P/E) ratio for LivaNova (LIVN) stock is 0 as of July 28, 2025.
Does LivaNova stock pay dividends?
No, LivaNova (LIVN) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next LivaNova dividend payment date?
LivaNova (LIVN) stock does not pay dividends to its shareholders.
What is the beta indicator for LivaNova?
LivaNova (LIVN) has a beta rating of 0.91. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.